Commentary by Bani Chander MD, PGY-3. and Ben Bergman MD, PGY-3
Please also see last week’s Class Act Post on the pathogenesis of Rheumatic Heart Disease
A 34-year-old Hispanic male presents with the chief complaint of …
Clinical Correlations
The NYU Langone Health Online Journal of Medicine
Class Act: The Use of MRI in Breast Cancer Screening
August 28, 2008
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. Prior to publication, each commentary is thoroughly reviewed for content by a faculty member.
Commentary by Daniel Green …
Addiction 2.0 Part 1
August 27, 2008
Commentary by Joshua Lee MD, Ellie Grossman MD and Marc Gourevitch MD, NYU Division of General Internal Medicine
Substance abuse remains a leading cause of disease and mortality in the US, yet it is rarely …
ShortCuts- This Week in the Journals
August 25, 2008
Commentary by Josh Remick MD, NYU Senior Chief Resident
Well, it’s been quite a week! First there was Obama’s VP buzz putting the world in a frenzy, which finally culminated with his 3am …
Clinical Pathology Conference 8/08 – The Answer
August 22, 2008Case presentation by Kristin Remus DO, NYU Chief Resident
Please review the posting of our prior CPC here.
When you’re ready you can download the CPC Answer.
Frailty- an emerging syndrome
August 21, 2008Commentary by David Sutin MD, NYU Section 0f Geriatric Medicine
The Annual American Geriatric Society meeting, held May 2008, in Washington DC, was as usual fascinating. The meeting highlights included a lively discussion of the treatment of hypertension in the very elderly, and a talk on the emerging syndrome of …
Old age and frailty: Biology and Socio-cultural Constructs
Commentary by Antonella Surbone MD PhD FACP, Department of Medicine, New York University Medical School, Clinical Correlations Ethics Section Editor
According to the Institute of Medicine (IOM) report of April 14th, 2008, the …
Breaking News: Revenge of the Gila Monster?
August 20, 2008
Commentary by Rachana Jani MD, PGY-2
As recently reported in ShortCuts, Byetta recently made headlines after the suggestion of a mortality benefit for patients taking the drug in a small subset of the Accord study. So is this the new golden drug …